LRRK2 and Parkinson disease: A 4-year longitudinal study in 32 asymptomatic LRRK2 mutation carriers showed that a lower striatal DAT binding at baseline predicted subsequent conversion to clinical PD (which was 12%) (Sierra et al. 2017).